This study from J&J reviews real-world outcomes when patients with schizophrenia switch from oral risperidone or paliperidone to once-monthly paliperidone palmitate (PP1M), a long-acting injectable. Schizophrenia is a condition often marked by difficulties with consistent medication adherence, which can lead to relapse and hospitalization. The analysis found that patients who switched to PP1M showed improved medication adherence, fewer relapses, and reduced hospitalizations compared to those who remained on oral medications. Economic findings also suggested lower healthcare costs, primarily due to fewer inpatient stays. The study concluded that switching from oral formulations to PP1M may provide clinical and cost benefits, though results are based on real-world data and observational design.
To learn more, download the supporting document here.
Contributor: Johnson & Johnson
